Although PD-1 blockade with nivolumab did not affect MM cell viability or enhance daratumumab-mediated lysis in short-term ex vivo experiments, nivolumab resulted in a mild but clear increase in T-cell numbers. The gene discussed is PDCD1; the disease is Miyoshi myopathy.